Nutritional issues in cancer management

Nutrition

Volumn 12, Issue 5, 1996, Pages 358-371

  Laviano, Alessandro ^a   Meguid, Michael M ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

cancer; malnutrition; nutrition; nutritional support

Indexed keywords

ARGININE; ASCORBIC ACID; BRANCHED CHAIN AMINO ACID; CYTOKINE; GAMMA INTERFERON; GLUTAMINE; INTERLEUKIN 1; INTERLEUKIN 6; MEGESTROL ACETATE; NUCLEOTIDE; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; RETINOID; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; CACHEXIA; CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PREVENTION; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DIETARY FIBER; DIETARY INTAKE; ENTERIC FEEDING; FAT INTAKE; FEMALE; HUMAN; IMPOTENCE; INTRAVENOUS DRUG ADMINISTRATION; LIPID METABOLISM; MALE; MALNUTRITION; NONHUMAN; NUTRITIONAL SUPPORT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN METABOLISM; RAT; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME; VAGINA BLEEDING; VITAMIN INTAKE;

EID: 0030152068     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-9007(96)80061-X     Document Type: Review

References (184)

1. 1. Clifford C, Kramer BK. Diet as risk and therapy for cancer. Med Clin North Am 1993; 77:725
2. 2. Chen MC, Meguid MM. Postulated cancer prevention diets. A guide to food selections. Surg Clin North Am 1986;66:931
3. 3. Daly JM, Redmond HP, Gallagher H. Perioperative nutrition in cancer patients. JPEN 1992; 16 (suppl. 6):100S
4. 4. Meguid MM, Mughal MM, Meguid V, Terz JJ. Risk-benefit analysis of malnutrition and perioperative nutritional support: a review. Nutr Int 1987; 3:25
5. 5. Wynder EL, Gori GB. Contribution of the environment to cancer incidence: an epidemiologic exercise. J Natl Cancer Inst 1977;58:825
6. 6. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981;66:1191
7. 7. National Academy of Sciences, National Research Council, Commission of Life Sciences. Diet and health Implications for reducing chronic disease risk. Washington, D.C.; National Academy Press, 1989
8. 8. Hursting SD, Thornquist M, Henderson MM. Types of dietary fat and the incidence of cancer at five sites. Prev Med 1990;19:242
9. 9. Broitman SA, Cannizzo F, Jr. A model system for studying nutritional interventions on colon tumor growth: effects of marine oil. Adv Exp Med Biol 1992;322:103
10. 10. Butrum RR, Clifford CK, Lanza E. NCI dietary guidelines: rationale. Am J Clin Nutr 1988;48 (suppl. 3):888
11. 11. Burkitt DP. Epidemiology of cancer of the colon and rectum. Cancer 1971;28:3
12. 12. Chen JC, Campbell JC, Li JY. Diet, life-style and mortality in China. A study of the characteristics of 65 Chinese counties. Ithaca, NY: Cornell University Press, 1990
13. 13. Trock B, Lanza E, Greenwald P. Dietary fiber, vegetables, and colon cancer: critical review and meta-analyses of the epidemiologic evidence. J Natl Cancer Inst 1990;82:650
14. 14. National Cancer Institute, NCI Division of Cancer Prevention and Control. Cancer statistics review: 1973-1988. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, 1991
15. 15. Kromhout D. Essential micronutrients in relation to carcinogenesis. Am J Clin Nutr 1987;45 (suppl. 5):1361
16. 16. Ziegler RG. Vegetables, fruits and carotenoids and the risk of cancer. Am J Clin Nutr 1991;53 (suppl. 1):251S
17. 17. Rogers AE, Longnecker MP. Dietary and nutritional influences on cancer: a review of epidemiologic and experimental data. Lab Invest 1988;59:729
18. 18. Rozen P, Fireman Z, Fine N, Wax Y, Ron E. Oral calcium suppresses increased rectal epithelial proliferation of persons at risk of colorectal cancer. Gut 1989; 30:650
19. 19. Krinsky NI, Deneke SM. Interaction of oxygen and oxy-radicals with carotenoids. J Natl Cancer Inst 1982;69:205
20. 20. Raineri R, Weisburger JH. Reduction of gastric carcinogenesis with ascorbic acid. Ann NY Acad Sci 1975;258:181
21. 21. Henson DE, Block G, Levine M. Ascorbic acid: biologic functions and relation to cancer. J Natl Cancer Inst 1991;83:547
22. 22. Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced cancer. Chem Biol Interact 1974;9:285
23. 23. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1976;73:3685
24. 24. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1978;75:4538
25. 25. Creagan ET, Moertel CG, O'Fallon JR, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. N Engl J Med 1979;301:687
26. 26. Moertel CG, Fleming TR, Creagan ET, et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison. N Engl J Med 1985;312:137
27. 27. Smith MA, Parkinson DR, Cheson BD, et al. Retinoids in cancer therapy. J Clin Oncol 1992;10:839
28. 28. Meguid MM, Muscaritoli M, Beverly JL, et al. The early cancer anorexia paradigm: changes in plasma free tryptophan and feeding indexes. JPEN 1992; 16 (suppl. 6):56S
29. 29. Nixon DW, Heymsfield SB, Cohen AE, et al. Protein-calorie undernutrition in hospitalized cancer patients. Am J Med 1980;68:683
30. 30. DeWys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980;69:491
31. 31. Warren S. The immediate causes of death in cancer. Am J Med Sci 1932;184:610
32. 32. Meguid MM, Debonis D, Meguid V, Hill LR, Terz JJ. Complications of abdominal operations for malignant disease. Am J Surg 1988; 156:341
33. 33. Dowd PS, Heatley RV. The influence of undernutrition on immunity. Clin Sci 1984;66:241
34. 34. Grosvenor M, Bulcavage L, Chlebowski RT. Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. Cancer 1989; 63:330
35. 35. DeWys WD, Walters K. Abnormalities of taste sensation in cancer patients. Cancer 1975;36:1888
36. 36. Shivshanker K, Bennett RW, Jr, Haynie TP. Tumor associated gastroparesis: correction with metoclopramide. Am J Surg 1983;145:221
37. 37. Bernstein IL, Bernstein ID. Learned food aversion and cancer anorexia. Cancer Treat Rep 1981;65 (suppl. 5):43
38. 38. Morrison SD. Limited capacity for motor activity as a cause for declining food intake in cancer. J Natl Cancer Inst 1973;51:1535
39. 39. Rossi Fanelli F, Cangiano C. Increased availability of tryptophan in brain as a common pathogenic mechanism for anorexia associated with different diseases. Nutrition 1991;7:364
40. 40. Knox LS, Crosby LO, Feurer ID, et al. Energy expenditure in malnourished cancer patients. Ann Surg 1983;197:152
41. 41. Fearon KC, Hansell DT, Preston T, et al. Influence of whole body protein turnover rate on resting energy expenditure in patients with cancer. Cancer Res 1988;48:2590
42. 42. Campos ACL, Waitzberg DL, Meguid MM. A comparison of the changes in carbohydrate, fat, and protein metabolism occurring with malignant and benign tumor and the impact of nutritional support. In: Alfin-Slater RB, Kritchevsky D, eds., Cancer and nutrition. Philadelphia: Plenum Publishing, 1991:69
43. 43. Norton JA, Shamberger R, Stein TP, Milne GW, Brennan MF. The influence of tumor-bearing on protein metabolism in the rat. J Surg Res 1981;30:456
44. 44. Norton JA, Burt ME, Brennan MF. In vivo utilization of substrate by human sarcoma-bearing limbs. Cancer 1980;45:2934
45. 45. Cascino A, Cangiano C, Ceci F, et al. Plasma amino acids in human cancer. Individual role of tumor, malnutrition and glucose tolerance. Clin Nutr 1988;7:213
46. 46. Kurzer M, Janiszewski J, Meguid MM. Amino acid profiles in tumor-bearing and pair-fed nontumor-bearing malnourished rats. Cancer 1988;62:1492
47. 47. Kubota A, Meguid MM, Hitch DC. Amino acid profiles correlate diagnostically with organ site in three kinds of malignant tumors. Cancer 1992;69:2343
48. 48. Meguid MM, Muscaritoli M, Cascino A, Rossi Fanelli F. Plasma amino acid profile in cancer patients: a novel diagnostic tool comes of age. In: Latifi R, ed. Amino acids in critical care and cancer. Austin, TX: CRC Press. 1994:159
49. 49. Rossi Fanelli F, Cascino A, Muscaritoli M. Abnormal substrate metabolism and nutritional strategies in cancer management. JPEN 1991;15:680
50. 50. Eden E, Edstrom S, Bennegard K, Schersten T, Lundholm K. Glucose flux in relation to energy expenditure in malnourished patients with and without cancer during periods of fasting and feeding. Cancer Res 1984;44:1718
51. 51. Lundholm K, Holm G, Schersten T. Insulin resistance in patients with cancer. Cancer Res 1978;38:4665
52. 52. Marks PA, Bishop JS. The glucose metabolism of patients with malignant disease and of normal subjects as studied by means of an intravenous glucose tolerance test. J Clin Invest 1957;36:254
53. 53. Shaw JH, Wolfe RR. Glucose and urea kinetics in patients with early and advanced gastrointestinal cancer: the response to glucose infusion, parenteral feeding and surgical resection. Surgery 1987;101:181
54. 54. Hers HG, Hue L. Gluconeogenesis and related aspects of glycolysis. Ann Rev Biochem 1983;53:617
55. 55. Warburg O. The metabolism of carcinoma cells. J Cancer Res 1925;9:148
56. 56. Masuno H, Yoshimura H, Ogawa N, Okuda H. Isolation of a lipolytic factor (Toxohormone-L) from ascites fluid of patients with hepatoma and its effect on feeding behavior. Eur J Cancer Clin Oncol 1984;20:1177
57. 57. Muscaritoli M, Cangiano C, Cascino A, et al. Plasma clearance of exogenous lipids in patients with malignant disease. Nutrition 1990;6:147
58. 58. Chapman HA, Jr, Hibb JB, Jr. Modulation of macrophage tumoricidal capability by components of normal serum: a central role of lipid. Science 1977; 197:282
59. 59. Ookhtens M, Kannan R, Lyon I, Baker N. Liver and adipose tissue contribution to newly formed fatty acids in an ascites tumor. Am J Physiol 1984;247:R146
60. 60. Cederbaum AI, Rubin E. Fatty acid oxidation, substrate shuttles, and activity of the citric acid cycle in hepatocellular carcinomas of varying differentiation. Cancer Res 1976;36:2980
61. 61. Tisdale MJ, Brennan RA. Loss of acetoacetate coenzyme-A transferase activity in tumors of peripheral tissues. Br J Cancer 1983;47:293
62. 62. Campos ACL, Meguid MM. A critical appraisal of the usefulness of perioperative nutritional support. Am J Clin Nutr 1992;55:117
63. 63. Lipman TO. Clinical trials of nutritional support in cancer. Parenteral and enteral nutrition. Hematol Oncol Clin North Am 1991;5:91
64. 64. Cella DF. Overcoming difficulties in demonstrating health outcome benefits. JPEN 1992;16 (suppl. 6):106S
65. 65. Rossi Fanelli F, Franchi F, Mulieri M, et al. Effect of energy substrate manipulation on tumor cell proliferation in parenterally fed neoplastic patients. Clin Nutr 1991;10:228
66. 66. Frank JL, Lawrence W, Jr, Banks WL, Jr, et al. Modulation of cell cycle kinetics in human cancer with total parenteral nutrition. Cancer 1992;69:1858
67. 67. Stallion A, Foley-Nelson T, Chance WT, et al. Parenteral vs enteral nutrition in tumor bearing rats. JPEN 1994;18:148
68. 68. Bennegard K, Eden E, Ekman L, et al. Metabolic response of whole body and peripheral tissues to enteral nutrition in weight losing cancer and non cancer patients. Gastroenterology 1983;85:92
69. 69. deVries EG, Mulder NH, Houwen B, et al. Enteral nutrition by nasogastric tube in adult patients treated with intensive chemotherapy for acute leukemia. Am J Clin Nutr 1982;35:1490
70. 70. Dresler CM, Jeevanandam M, Brennan MF. Metabolic efficacy of enteral feeding in malnourished cancer and non-cancer patients. Metab Clin Exp 1987;36:82
71. 71. Haffeejee AA, Angorn IB. Nutritional status and the nonspecific cellular and humoral immune response in esophageal carcinoma. Ann Surg 1979;189:475
72. 72. Burt ME, Gorschboth CM, Brennan MF. A controlled prospective, randomized trial comparing the metabolic effects of enteral and parenteral nutrition in the cancer patient. Cancer 1982;49:1092
73. 73. Muller JM, Brenner U, Dienst D, Pichlmaier H. Preoperative parenteral feeding in patients with gastrointestinal carcinoma. Lancet 1982;1:68
74. 74. Shamberger RC, Brennan MF, Goodgame JT, Jr, et al. A prospective randomized study of adjuvant parenteral nutrition in the treatment of sarcomas: results of metabolic and survival studies. Surgery 1984;96:1
75. 75. McArdle AH, Wittnich C, Freeman CR, Duguid WP. Elemental diet as prophylaxis against radiation injury. Histological and ultrastructural studies. Arch Surg 1985;120:1026
76. 76. Brennan MF. Total parenteral nutrition in the cancer patient. N Engl J Med 1981;305:375
77. 77. Meguid MM, Muscaritoli M. Current uses of total parenteral nutrition. Am Fam Phys 1993;47:383
78. 78. Bellantone R, Doglietto GB, Bossola M, et al. Preoperative parenteral nutrition in malnourished high risk surgical patients. Nutrition 1990;6:168
79. 79. Copeland EM, MacFayden BV, Dudrick SJ. Intravenous hyperalimentation in cancer patients. J Surg Res 1974;16:241
80. 80. Holter AR, Fischer JE. The effect of perioperative hyperalimentation on complication in patients with carcinoma and weight loss. J Surg Res 1977;23:31
81. 81. Thompson BR, Julian TB, Stremple JF. Perioperative total parenteral nutrition in patients with gastrointestinal cancer. J Surg Res 1981;30:497
82. 82. Klein S, Simes J, Blackburn GL. Total parenteral nutrition and cancer clinical trials. Cancer 1986;58:1378
83. 83. Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. Perioperative total parenteral nutrition in surgical patients. N Engl J Med 1991;325:525
84. 84. Jeejeebhoy KN, Meguid MM. Assessment of nutritional status in the oncologic patient. Surg Clin North Am 1986;66:1077
85. 85. Meguid MM, Mughal MM, Debonis D, Meguid V, Terz JJ. Influence of nutritional status on the resumption of adequate food intake in patients recovering from colorectal cancer operations. Surg Clin North Am 1986;66:1167
86. 86. Mughal MM, Meguid MM. The effect of nutritional status on morbidity after elective surgery for benign gastrointestinal disease. JPEN 1987;11:140
87. 87. Copeland EM, Souchon EA, MacFayden BV, Jr, Rapp MA, Dudrick SJ. Intravenous hyperalimentation as an adjunct to radiation therapy. Cancer 1977;36:609
88. 88. Clamon GH, Feld R, Evans WK, et al. Effect of adjuvant central IV hyperalimentation on the survival and response to treatment of patients with small cell lung cancer: a randomized trial. Cancer Treat Rep 1985;69:167
89. 89. Levine AS, Brennan MF, Ramu A, et al. Controlled clinical trials of nutritional interventions as an adjunct to chemotherapy, with a comment on nutrition and drug resistance. Cancer Res 1982;42 (suppl. 2):774S
90. 90. Valdivieso M, Bodey GP, Benjamin RS, et al. Role of hyperalimentation as an adjunct to intensive chemotherapy for small cell bronchogenic carcinoma. Cancer Treat Rep 1981;65:145
91. 91. Issell BF, Valdivieso M, Zaren HA, et al. Protection against chemotherapy toxicity by IV hyperalimentation. Cancer Treat Rep 1978;62:1139
92. 92. Ziegler TR, Young LS, Benfell K, et al. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med 1992;116:821
93. 93. Schloerb PR, Amare M. Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (a randomized, double-blind study). JPEN 1993;17:407
94. 94. Dinarello CA. Interleukin-1 and Interleukin-1 antagonism. Blood 1991;77:1627
95. 95. Moldawer LL, Andersson C, Gelin J, Lundholm KG. Regulation of food intake and hepatic protein metabolism by recombinant derived monokines. Am J Physiol 1988;254:G450
96. 96. Plata-Salaman CR. Immunoregulators in the nervous system. Neurosci Biobehav Rev 1991;15:185
97. 97. Bodnar RJ, Pasternak GW, Mann PE, et al. Mediation of anorexia by human recombinant tumor necrosis factor through a peripheral action in the rat. Cancer Res 1989;49:6280
98. 98. Warren RS, Starnes HF, Jr, Gabrilove JL, Oettgen MF, Brennan MF. The acute metabolic effects of tumor necrosis factor administration in humans. Arch Surg 1987;122:1396
99. 99. Tocco-Bradley R, Georgieff M, Jones CT, et al. Changes in energy expenditure and fat metabolism in rats infused with interleukin-1. Eur J Clin Invest 1987;117:504
100. 100. Fong Y, Moldawer LL, Marano M, et al. Cachectin/TNF alpha or interleukin-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol 1989;256:R659
101. 101. Flores EA, Bistrian BR, Pomposelli JJ, et al. Infusion of tumor necrosis factor/cachectin promotes muscle protein catabolism in the rat. A synergistic effect with interleukin-1. J Clin Invest 1989;83:1614
102. 102. Patton JS, Shepard HM, Wilking H, et al. Interferons and tumor necrosis factor have similar catabolic effect on 3T3LI cells. Proc Natl Acad Sci USA 1986;83:8313
103. 103. Langstein HN, Doherty GM, Fraker DL, Buresh CM, Norton JA. The roles of interferon-gamma and tumor necrosis factor in an experimental rat model of cancer cachexia. Cancer Res 1991;51:2302
104. 104. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J 1990;4:2860
105. 105. Gelin J, Moldawer LL, Lonnroth C, et al. Appearance of hybridoma growth factor/IL-6 in the serum of mice bearing a methylcholanthrene induced sarcoma. Biochem Biophys Res Commun 1988;157:575
106. 106. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657
107. 107. Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980;302:135
108. 108. Gorter R, Seefried M, Volberding P. Dronabinol effects on weight in patients with HIV infection (letter). AIDS 1992;6:127
109. 109. Chlebowski RT, Bulcavage L, Grosvenor M, et al. Hydrazine sulfate in cancer patients with weight loss. Cancer 1987;59:406
110. 110. Kosty M, Fleishman S, Herndon JE II. Cisplatin, vinblastine and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized, placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994;12:1113
111. 111. Loprinzi CL, Goldberg RG, Su JQ. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994;12:1126
112. 112. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974;33:1607
113. 113. Willox J, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer. Br Med J 1984;288:27
114. 114. Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989;25:1823
115. 115. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985;69:751
116. 116. Spuggs D. Tumor Necrosis Factor: clinical applications. In: Biologic therapy of cancer. DeVita VT, Hellman S, Rosenberg SA, eds. Philadelphia: J.B. Lippincott Company, 1991:354
117. 117. Hardin TC. Cytokine mediators of malnutrition: clinical implications. Nutr Clin Prac 1993;8:55
118. 118. Freed DLJ, Banks AJ, Longson D, Burley DM. Anabolic steroids in athletics: crossover double-blind trial on weightlifters. Br Med J 1975;5:471
119. 119. Chlebowski RT, Herrold J, Ali I, et al. Influence of nandrolone decanoate on weight loss in advanced non-small-cell lung cancer. Cancer 1986;58:183
120. 120. Mulligan K, Grunfeld C, Hellerstein M, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;77:956
121. 121. Fazely F, Dezube BJ, Allen-Ryan J, Pardee AB, Ruprecht RM. Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood 1991;77:1653
122. 122. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton CA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991;110:192
123. 123. Thanhauser A, Reiling N, Bohle A, et al. Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity. Immunology 1993;80:151
124. 124. Lissoni P, Ardizzoia A, Perego MS, et al. Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha. J Biol Regul Homeost Agents 1993;7:73
125. 125. Dezube BJ, Sherman ML, Fridovich-Keil JL, Allen-Ryan J, Pardee AB. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol Immunother 1993;36:57
126. 126. Tuckey JA, Parr BR, Mc Call JL. Pentoxifylline and wellbeing in cancer (letter). Lancet 1993;342:617
127. 127. Bianco JA, Appelbaum FR, Nemunaitis J, et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991;78:1205
128. 128. Attal M, Huguet F, Rubie H, et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 1993;82:732
129. 129. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265
130. 130. Plata-Salaman CR. Tumor Necrosis Factor production in response to lipids: immunomodulatory activity with clinical applicability? Nutrition 1994;10:179
131. 131. Sierra P, Ling PR, Istfan N, Bistrian BR. Fish-oil feeding improves insulin sensitivity in TNF-treated rats (abstract). JPEN 1994;18 (suppl. 1):23S
132. 132. Anti M, Marra G, Armelao F, et al. Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterology 1992;103:883
133. 133. Rose DP, Connolly JM. Effects of dietary omega-3 fatty acids on human breast cancer growth and metastases in nude mice. J Natl Cancer Inst 1993;85:1743
134. 134. Dinarello CA, Endres S, Meydani SN, Meydani N, Hellerstein MK. Interleukin-1, anorexia, and dietary fatty acids. Ann NY Acad Sci 1990;587:332
135. 135. Tisdale MJ, Dhesi JK. Inhibition of weight loss by omega-3 fatty acids in an experimental cachexia model. Cancer Res 1990;50:5022
136. 136. Froesch ER, Schmid C, Schwander J, Zapf J. Actions of insulin-like growth factor. Ann Rev Physiol 1985;47:433
137. 137. Phillips LS. Nutrition, somatomedins and the brain. Metab Clin Exp 1986;35:78
138. 138. Ng EH, Rock CS, Lazarus DD, et al. Insulin-like growth factor I preserves host lean tissue mass in cancer cachexia. Am J Physiol 1992;262:R426
139. 139. Tchekmedyian NS, Tait N, Moody M, Aisner J. High-dose megestrol acetate: a possible treatment for cachexia, JAMA 1987;257:1195
140. 140. Tchekmedyian NS, Hickman M, Siau J, et al. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992;69:1268
141. 141. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127
142. 142. Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990; 66:1279
143. 143. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993;11:762
144. 144. Feliu J, Gonzalez-Baron M, Berrocal A, et al. Usefulness of megestrol acetate in cancer cachexia and anorexia. Am J Clin Oncol 1992;15:436
145. 145. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11:152
146. 146. Loprinzi CL, Jensen MD, Jiang NS, Schaid DJ. The effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clinic Proc 1992;67:1160
147. 147. Foitl DR, Hyman G, Lefkowitch JH. Jaundice and intrahepatic cholestasis following high-dose megestrol acetate for breast cancer. Cancer 1989;63:438
148. 148. Henry K, Rathgaber S, Sullivan C, McCabe K. Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia. Ann Intern Med 1992;116:53
149. 149. Nathwani D, Green S, Heslop JM, Goldberg DJ, Kennedy DH. Beneficial response to megoestrol acetate in AIDS-related cachexia and a possible megoestrol withdrawal-associated syndrome? Acta Derm Venereol (Stockh.) 1990;70:520
150. 150. Hunter DC, Weintraub M, Blackburn GL, Bistrian BR. Branched chain amino acids as the protein component of parenteral nutrition in cancer cachexia. Br J Surg 1989;76:149
151. 151. Crosby LE, Bistrian BR, Ling P-R, et al. Effects of branched chain amino acids-enriched total parenteral nutrition on amino acid utilization in rats bearing Yoshida sarcoma. Cancer Res 1988;48:2698
152. 152. Smith QR. The blood-brain barrier and the regulation of amino acid uptake and availability to brain. Adv Exp Med Biol 1991;291:55
153. 153. Cangiano C, Laviano A, Preziosa I, et al. Effects of oral branched-chain amino acids (BCAA) administration in the treatment of cancer anorexia (abstract). Clin Res 1994;2:129A
154. 154. Souba WW. Glutamine and cancer. Ann Surg 1993;218:715
155. 155. Chen MK, Salloum RM, Austgen TR, et al. Tumor regulation of hepatic glutamine metabolism. JPEN 1991;15:159
156. 156. Austgen TR, Chen MK, Dudrick PS, Copeland EM III, Souba WW. Cytokine regulation of intestinal glutamine utilization. Am J Surg 1992;163:174
157. 157. van Lanschot JJ, Mealy K, Wilmore DW. The effects of tumor necrosis factor on intestinal structure and metabolism. Ann Surg 1990;212:663
158. 158. Klimberg VS, Souba WW, Dolson DJ, et al. Prophylactic glutamine protects the intestinal mucosa from radiation injury. Cancer 1990;66:62
159. 159. Klimberg VS, Nwokedi E, Hutchins LF, et al. Glutamine facilitates chemotherapy while reducing toxicities. JPEN 1992;16 (suppl. 6):83S
160. 160. Salloum RM, Copeland EM III, Bland KI, Souba WW. Selective stimulation of brush border glutamine transport in the tumor-bearing rat. J Surg Res 1991;50:391
161. 161. Klimberg VS, Souba WW, Salloum RM, et al. Glutamine-enriched diets support muscle glutamine metabolism without stimulating tumor growth. J Surg Res 1990;48:319
162. 162. Reynolds JV, Daly JM, Shou J, et al. Immunologic effects of arginine supplementation in tumor-bearing and non-tumor-bearing hosts. Ann Surg 1990;211:202
163. 163. Ye SL, Istfan NW, Driscoll DF, Bistrian BR. Tumor and host response to arginine and branched chain amino acid-enriched total parenteral nutrition. A study involving Walker 256 carcino-sartumor coma-bearing rats. Cancer 1992;69:261
164. 164. Kirk SJ, Barbul A. Role of arginine in trauma, sepsis and immunity. JPEN 1990;14 (suppl 14):226S
165. 165. Barbul A. Arginine: biochemistry, physiology, and therapeutic implications. JPEN 1986;10:227
166. 166. Niijima A, Renvyle T, Meguid MM. Mechanisms of arginine and lysine immune enhancing activity. Surgical Forum 1995;46:27
167. 167. Grossie VB, Jr, Nishioka K, Ajani JA, Ota DM. Substituting ornithine for arginine in total parenteral nutrition eliminates enhanced tumor growth. J Surg Oncol 1992;50:161
168. 168. Carlson SE. Human milk non protein nitrogen: occurrence and possible function. Adv Pediatr 1985;32:43
169. 169. Van Buren CT, Rudolph FB, Kulkarni A, et al. Reversal of immunosuppression induced by a protein-free diet: comparison of nucleotides, fish oil, and arginine. Crit Care Med 1990;18 (suppl. 2):S114
170. 170. Iijima S, Tsujinaka T, Kido Y, et al. Intravenous administration of nucleotides and a nucleotide mixture diminishes intestinal mucosal atrophy induced by total parenteral nutrition. JPEN 1993;17:265
171. 171. Daly JM, Lieberman MD, Goldfine J, et al. Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: immunologic, metabolic, and clinical outcome. Surgery 1992;112:56
172. 172. Van Buren CT, Kulkarni AD, Rudolph FB. The role of nucleotides in adult nutrition. J Nutr 1994;124 (suppl. 1):160S
173. 173. He Y, Chu SH, Walker WA. Nucleotide supplement alter proliferation and differentiation of cultured human (Caco-2) and rat (IEC-6) intestinal epithelial cells. J Nutr 1993;123:1017
174. 174. Kuhr T, Dougherty GJ, Klingemann HG. Transfer of the tumor necrosis factor-alpha gene into hematopoietic progenitor cells as a model for site-specific cytokine delivery after marrow transplantation. Blood 1994;84:2966
175. 175. Bal DG, Foerster SB. Dietary strategies for cancer prevention. Cancer 1993;72:1005
176. 176. Samuels ML, Selig DE, Ogden S, Grant C, Brown B. IV hyperalimentation and chemotherapy for stage III testicular cancer: a randomized study. Cancer Treat Rep 1981;65:615
177. 177. Nixon DW, Moffitt S, Lawson DH, et al. Total parenteral nutrition as an adjunct to chemotherapy of metastatic colorectal cancer. Cancer Treat Rep 1981;65 (suppl. 5):121
178. 178. Popp MB, Fisher RI, Wesley R, et-al. A prospective randomized study of adjuvant parenteral nutrition in the treatment of advanced diffuse lymphoma: influence on survival. Surgery 1981;90:195
179. 179. Shamberger RC, Brennan MF, Goodgame JT, Jr, et al. A prospective, randomized study of adjuvant parenteral nutrition in the treatment of sarcomas: results of metabolic and survival studies. Surgery 1984;96:1
180. 180. Goodwin WJ, Torres J. The value of the prognostic nutritional index in the management of patients with advanced carcinoma of the bead and neck. Head Neck Surg 1984;6:932
181. 181. Rickard KA, Logmani ES, Grosfeld JL, et al. Short-and longterm effectiveness of enteral and parenteral nutrition in reversing or preventing protein-energy malnutrition in advanced neuro-blastoma. A prospective randomized study. Cancer 1985;56:2881
182. 182. Bashir Y, Graham TR, Torrance A, Gibson GJ, Corris PA. Nutritional state of patients with lung cancer undergoing thoracotomy. Thorax 1990;45:183
183. 183. Larrea J, Vega S, Martinez T, et al. The nutritional status and immunological situation of cancer patients. Nutricion Hospitalaria 1992;7:178
184. 184. Tan YS, Nambiar R, Yo SL. Prevalence of protein calorie malnutrition in general surgical patients. Ann Acad Med (Singapore) 1992;21:334